858-449-1310 contact@somatek.com


First T-cell Engager Has Been Approved

As widely reported, earlier this week FDA approved the first in a novel class of immuno-oncology drugs called bispecific T-cell engagers for the treatment of small cell carcinoma. Small cell carcinoma, an aggressive type of lung cancer, currently has a few effective...

read more

Possible dementia biomarkers in blood identified

Researchers at Fudan University in Shanghai have identified four blood proteins that could serve as early biomarkers for dementia. This is important news because early, pre-symptomatic diagnosis of Alzheimer’s and other forms of dementia could be a big step in...

read more

Pigneys – the Future of Renal Transplantation?

Last week was a big one for the future of kidney transplants – specifically, kidneys grown in pigs. At the Guangzhou Institute of Biomedicine and Health, scientists reported that they have used human pluripotent stem cells to grown part-human, part-porcine kidneys in...

read more

Pfizer to buy Seagen for $43 billion

Pfizer has announced that it intends to buy Seagen, formerly known as Seattle Genetics, for the huge sum of $43 billion. Seagen is pioneer and driving force behind the development of antibody-drug conjugates for the treatment of cancer. In the best of all worlds this...

read more

A New Type of Antibody –

For a long time 5 antibody types have been known in mammals, IgG, IgM, IgA, IgE, and IgD, with IgG being the work horse in biotechnology. So it drew our attention that a group at Duke University has described a new type of anti-glycan antibody that binds to a patch of...

read more

Monoclonal for Alzheimer’s

On Monday FDA approved Biogen’s aducanumab, brand name Aduhelm, through a program called accelerated approval. Aduhelm is the first new medication for Alzheimer’s disease in nearly two decades. FDA’s decision was welcomed by patients and their families as a...

read more